Amyloid formation disrupts the balance between interleukin-1β and interleukin-1 receptor antagonist in human islets

Molecular Metabolism

Volumn 6, Issue 8, 2017, Pages 833-844

  Hui, Queenie ^a   Asadi, Ali ^a   Park, Yoo Jin ^a   Kieffer, Timothy J ^a   Ao, Ziliang ^a   Warnock, Garth L ^a   Marzban, Lucy ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amylin; Interleukin 1 receptor antagonist; Interleukin 1 ; Islet amyloid; Islet amyloid polypeptide; Islet inflammation; Type 2 diabetes; cell apoptosis

Indexed keywords

AMYLIN; AMYLOID; FAS ANTIGEN; GLUCOSE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; NEUTRALIZING ANTIBODY; SMALL INTERFERING RNA; CASPASE 8; FAS LIGAND;

ADULT; AMYLOIDOSIS; ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; ISOLATED PANCREAS ISLET; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; UPREGULATION; ADOLESCENT; ANIMAL; CELL CULTURE; CELL LINE; DRUG EFFECT; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL;

ADOLESCENT; ADULT; AMYLOID; ANIMALS; APOPTOSIS; CASPASE 8; CELL LINE; CELLS, CULTURED; FAS LIGAND PROTEIN; HUMANS; INSULIN-SECRETING CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MICE; MIDDLE AGED;

EID: 85020688191     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2017.05.016     Document Type: Article

References (43)

1. Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A., Butler, P.C., Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:1 (2003), 102–110.
2. Kahn, S.E., Cooper, M.E., Del Prato, S., Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:9922 (2014), 1068–1083.
3. Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology 11:2 (2011), 98–107.
4. Quan, W., Jo, E.K., Lee, M.S., Role of pancreatic beta-cell death and inflammation in diabetes. Diabetes Obesity Metabolism 15:Suppl. 3 (2013), 141–151.
5. Donath, M.Y., Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature Reviews Drug Discovery 13:6 (2014), 465–476.
6. Donath, M.Y., Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia 59:4 (2016), 679–682.
7. Ehses, J.A., Lacraz, G., Giroix, M.H., Schmidlin, F., Coulaud, J., Kassis, N., et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proceedings of the Natural Academy of Sciences of the United States of America 106:33 (2009), 13998–14003.
8. Dinarello, C.A., Donath, M.Y., Mandrup-Poulsen, T., Role of IL-1beta in type 2 diabetes. Current Opinion in Endocrinology, Diabetes, and Obesity 17:4 (2010), 314–321.
9. Ehses, J.A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J.A., Maor-Cahn, R., et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56:9 (2007), 2356–2370.
10. Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nature Immunology 11:10 (2010), 897–904.
11. Westwell-Roper, C.Y., Ehses, J.A., Verchere, C.B., Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1beta production and beta-cell dysfunction. Diabetes 63:5 (2014), 1698–1711.
12. Park, Y.J., Warnock, G.L., Ao, Z., Safikhan, N., Meloche, M., Asadi, A., et al. Dual role of IL-1beta in islet amyloid formation and its beta-cell toxicity: implications for type 2 diabetes and islet transplantation. Diabetes, Obesity and Metabolism 19:5 (2017), 682–694.
13. Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H.I., Spinas, G.A., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. Journal of Clinical Investigation 110:6 (2002), 851–860.
14. Park, Y.J., Lee, S., Kieffer, T.J., Warnock, G.L., Safikhan, N., Speck, M., et al. Deletion of Fas protects islet beta cells from cytotoxic effects of human islet amyloid polypeptide. Diabetologia 55:4 (2012), 1035–1047.
15. Park, Y.J., Woo, M., Kieffer, T.J., Hakem, R., Safikhan, N., Yang, F., et al. The role of caspase-8 in amyloid-induced beta cell death in human and mouse islets. Diabetologia 57:4 (2014), 765–775.
16. Garlanda, C., Dinarello, C.A., Mantovani, A., The interleukin-1 family: back to the future. Immunity 39:6 (2013), 1003–1018.
17. Scarim, A.L., Arnush, M., Hill, J.R., Marshall, C.A., Baldwin, A., McDaniel, M.L., et al. Evidence for the presence of type I IL-1 receptors on beta-cells of islets of Langerhans. Biochimica et Biophysica Acta 1361:3 (1997), 313–320.
18. Boni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D.T., Prazak, R., et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150:12 (2009), 5218–5229.
19. Sauter, N.S., Thienel, C., Plutino, Y., Kampe, K., Dror, E., Xu, S., et al. Angiotensin II induces IL-1beta-mediated islet inflammation and beta-cell dysfunction independently of vasoconstrictory effects. Diabetes 64:4 (2015), 1273–1283.
20. Westermark, P., Andersson, A., Westermark, G.T., Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews 91:3 (2011), 795–826.
21. Jurgens, C.A., Toukatly, M.N., Fligner, C.L., Udayasankar, J., Subramanian, S.L., Zraika, S., et al. Beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. The American Journal of Pathology 178:6 (2011), 2632–2640.
22. Marzban, L., Tomas, A., Becker, T.C., Rosenberg, L., Oberholzer, J., Fraser, P.E., et al. Small interfering RNA-mediated suppression of proislet amyloid polypeptide expression inhibits islet amyloid formation and enhances survival of human islets in culture. Diabetes 57:11 (2008), 3045–3055.
23. Park, Y.J., Ao, Z., Kieffer, T.J., Chen, H., Safikhan, N., Thompson, D.M., et al. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation. Diabetologia 56:3 (2013), 508–519.
24. Westermark, G., Westermark, P., Eizirik, D.L., Hellerstrom, C., Fox, N., Steiner, D.F., et al. Differences in amyloid deposition in islets of transgenic mice expressing human islet amyloid polypeptide versus human islets implanted into nude mice. Metabolism 48:4 (1999), 448–454.
25. Westermark, G.T., Westermark, P., Berne, C., Korsgren, O., Widespread amyloid deposition in transplanted human pancreatic islets. The New England Journal of Medicine 359:9 (2008), 977–979.
26. Potter, K.J., Abedini, A., Marek, P., Klimek, A.M., Butterworth, S., Driscoll, M., et al. Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts. Proceedings of the National Academy of Sciences of the United States of America 107:9 (2010), 4305–4310.
27. Udayasankar, J., Kodama, K., Hull, R.L., Zraika, S., Aston-Mourney, K., Subramanian, S.L., et al. Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets. Diabetologia 52:1 (2009), 145–153.
28. Kahn, S.E., D'Alessio, D.A., Schwartz, M.W., Fujimoto, W.Y., Ensinck, J.W., Taborsky, G.J. Jr., et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39:5 (1990), 634–638.
29. Haataja, L., Gurlo, T., Huang, C.J., Butler, P.C., Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocrine Reviews 29:3 (2008), 303–316.
30. Huang, C.J., Lin, C.Y., Haataja, L., Gurlo, T., Butler, A.E., Rizza, R.A., et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56:8 (2007), 2016–2027.
31. Zraika, S., Hull, R.L., Udayasankar, J., Aston-Mourney, K., Subramanian, S.L., Kisilevsky, R., et al. Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia 52:4 (2009), 626–635.
32. Rivera, J.F., Gurlo, T., Daval, M., Huang, C.J., Matveyenko, A.V., Butler, P.C., et al. Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic beta-cells: protective role of p62-positive cytoplasmic inclusions. Cell Death and Differentiation 18:3 (2011), 415–426.
33. Demuro, A., Mina, E., Kayed, R., Milton, S.C., Parker, I., Glabe, C.G., Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. The Journal of Biological Chemistry 280:17 (2005), 17294–17300.
34. Zhao, J., Hu, R., Sciacca, M.F., Brender, J.R., Chen, H., Ramamoorthy, A., et al. Non-selective ion channel activity of polymorphic human islet amyloid polypeptide (amylin) double channels. Physical Chemistry Chemical Physics 16:6 (2014), 2368–2377.
35. Westwell-Roper, C.Y., Chehroudi, C.A., Denroche, H.C., Courtade, J.A., Ehses, J.A., Verchere, C.B., IL-1 mediates amyloid-associated islet dysfunction and inflammation in human islet amyloid polypeptide transgenic mice. Diabetologia 58:3 (2014), 575–585.
36. Arend, W.P., Malyak, M., Guthridge, C.J., Gabay, C., Interleukin-1 receptor antagonist: role in biology. Annual Review of Immunology 16 (1998), 27–55.
37. Maedler, K., Sergeev, P., Ehses, J.A., Mathe, Z., Bosco, D., Berney, T., et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proceedings of the National Academy of Sciences of the United States of America 101:21 (2004), 8138–8143.
38. Symons, J.A., Young, P.R., Duff, G.W., Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proceedings of the Natural Academy of Sciences of the United States of America 92:5 (1995), 1714–1718.
39. Meier, D.T., Morcos, M., Samarasekera, T., Zraika, S., Hull, R.L., Kahn, S.E., Islet amyloid formation is an important determinant for inducing islet inflammation in high-fat-fed human IAPP transgenic mice. Diabetologia 57:9 (2014), 1884–1888.
40. Boni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J.A., Kerr-Conte, J., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. The Journal of Clinical Endocrinology and Metabolism 93:10 (2008), 4065–4074.
41. Heneka, M.T., Kummer, M.P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493:7434 (2013), 674–678.
42. Yasuhara, O., Matsuo, A., Terai, K., Walker, D.G., Berger, A.E., Akiguchi, I., et al. Expression of interleukin-1 receptor antagonist protein in post-mortem human brain tissues of Alzheimer's disease and control cases. Acta Neuropathologia 93:4 (1997), 414–420.
43. Tarkowski, E., Liljeroth, A.M., Nilsson, A., Minthon, L., Blennow, K., Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 12:5 (2001), 314–317.